Interleukin-33 Deficiency Protects the Skin From Ulcer Formation in an Ischemia-Reperfusion-Induced Decubitus Mouse...

Area of Science:

• Immunology
• Dermatology
• Wound Healing

Background:

• Interleukin-33 (IL-33) is an alarmin released during tissue damage.
• IL-33 plays a role in regulating gene expression and immune responses.
• Decubitus ulcers, or pressure ulcers, are a significant clinical challenge.

Purpose of the Study:

• To elucidate the mechanism of IL-33 in decubitus ulcer formation.
• To investigate the role of IL-33 signaling in an animal model of pressure-induced skin injury.

Main Methods:

• Utilized IL-33 knockout (KO), soluble ST2 transgenic, and wild-type (WT) mice.
• Induced ischemia-reperfusion (I/R) injury to model decubitus ulcers.
• Administered anti-IL-33 receptor and anti-IL-33 neutralizing antibodies.
• Analyzed ulcer area, immune cell infiltration, and gene expression.

Main Results:

• IL-33 KO mice exhibited significantly reduced ulcer area compared to WT mice.
• Blocking the IL-33 receptor (transmembrane ST2) prevented ulcer formation.
• IL-33 KO mice showed altered immune cell profiles, including increased M2 macrophages and reduced neutrophils and mast cells.
• IL-33 deficiency led to decreased IL-1β and increased CCL17 expression.

Conclusions:

• IL-33 is released upon ischemia-reperfusion injury and contributes to decubitus ulcer development.
• IL-33 promotes inflammatory responses, including macrophage and mast cell infiltration and IL-1β production.
• Targeting IL-33 signaling may offer a therapeutic strategy for early-stage decubitus ulcers.